MedPath

Alfuzosin

Generic Name
Alfuzosin
Brand Names
Uroxatral, Xatral
Drug Type
Small Molecule
Chemical Formula
C19H27N5O4
CAS Number
81403-80-7
Unique Ingredient Identifier
90347YTW5F

Overview

Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.

Indication

Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).

Associated Conditions

  • Benign Prostatic Hyperplasia (BPH)

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2024/03/18
Phase 1
Not yet recruiting
Pharma Nueva
2024/01/29
Phase 1
Not yet recruiting
International Bio service
2017/05/09
Phase 4
Completed
Kocatepe University
2016/11/30
Not Applicable
Completed
Fondazione IRCCS Policlinico San Matteo di Pavia
2014/10/17
Phase 1
Completed
2013/04/18
Phase 2
Completed
2009/07/17
Not Applicable
Completed
2009/05/05
Phase 3
Completed
Chesapeake Urology Research Associates
2009/02/04
Phase 4
Completed
2008/07/11
Phase 3
UNKNOWN
United States Naval Medical Center, San Diego

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Aidarex Pharmaceuticals LLC
33261-994
ORAL
10 mg in 1 1
11/14/2013
Bryant Ranch Prepack
63629-2354
ORAL
10 mg in 1 1
3/3/2023
Concordia Pharmaceuticals Inc.
59212-200
ORAL
10 mg in 1 1
1/31/2019
Bryant Ranch Prepack
71335-2146
ORAL
10 mg in 1 1
4/14/2023
Northwind Pharmaceuticals, LLC
51655-432
ORAL
10 mg in 1 1
1/23/2023
Liberty Pharmaceuticals, Inc.
0440-5000
ORAL
10 mg in 1 1
8/9/2016
Bryant Ranch Prepack
63629-7907
ORAL
10 mg in 1 1
5/6/2022
Northwind Pharmaceuticals, LLC
51655-967
ORAL
10 mg in 1 1
7/5/2023
Bryant Ranch Prepack
63629-2353
ORAL
10 mg in 1 1
2/9/2023
Rising Pharma Holdings, Inc.
57237-114
ORAL
10 mg in 1 1
1/6/2024

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APO-ALFUZOSIN PROLONGED RELEASE TABLET 10mg
SIN15512P
TABLET, EXTENDED RELEASE
10mg
7/19/2018
Alfuzosin PH&T 10mg prolonged-release tablets
SIN13819P
TABLET, EXTENDED RELEASE
10.000 mg
6/21/2010
RANFUZOSIN MODIFIED RELEASE TABLETS 10MG
SIN13984P
TABLET, EXTENDED RELEASE
10mg
7/5/2011
XATRAL XL TABLET 10 mg
SIN11579P
TABLET
10 mg
7/5/2001
XATRAL SR TABLET 5 mg
SIN09546P
TABLET, EXTENDED RELEASE
5 mg
11/21/1997

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Alfuzosin Hydrochloride Prolonged Release Tablets
国药准字HJ20170036
化学药品
片剂
4/11/2023
Alfuzosin Hydrochloride Prolonged Release Tablets
国药准字H20064331
化学药品
片剂
5/20/2020
Alfuzosin Hydrochloride Prolonged Release Tablets
国药准字HJ20170035
化学药品
片剂
4/11/2023
Alfuzosin Hydrochloride Tablets
国药准字H20030066
化学药品
片剂
2/6/2020
Alfuzosin Hydrochloride Tablets
国药准字H20041339
化学药品
片剂
3/27/2020

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
XALTRIN PROLONGED-RELEASE TABLETS 10MG
N/A
N/A
N/A
10/30/2021

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
XATRAL SR alfuzosin 10mg (as hydrochloride) tablet blister pack
81900
Medicine
A
9/17/2002

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath